Genesis Healthcare, Inc.
GENN
$0.0002
$0.000.00%
| Weiss Ratings | GENN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | GENN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | GENN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1,752.59 | |||
| Price History | GENN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | 0.00% | |||
| 90-Day Total Return | 0.00% | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | -81.82% | |||
| 2-Year Total Return | -98.37% | |||
| 3-Year Total Return | -99.88% | |||
| 5-Year Total Return | -99.99% | |||
| 52-Week High % Change | -99.85% | |||
| 52-Week Low % Change | 19,900.00% | |||
| Price | GENN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.13 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Aug 06, 2024 | |||
| 52-Week High Price (Date) | Oct 02, 2024 | |||
| Valuation | GENN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 24.50K | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.59 | |||
| Earnings Per Share Growth | -1,632.55% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.00 | |||
| Price/Book (Q) | 0.00 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | GENN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 113.29M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | GENN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 610 444 6350 | |||
| Address | 101 East State Street Kennett Square, PA 19348 | |||
| Website | www.genesishcc.com | |||
| Country | United States | |||
| Year Founded | 2003 | |||
| Profitability | GENN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -6.90% | |||
| Profit Margin | -1.50% | |||
| Management Effectiveness | GENN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -3.87% | |||
| Return on Equity | -- | |||
| Income Statement | GENN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 3.91B | |||
| Total Revenue (TTM) | 3.91B | |||
| Revenue Per Share | $34.48 | |||
| Gross Profit (TTM) | 1.65B | |||
| EBITDA (TTM) | -161.94M | |||
| EBIT (TTM) | -269.78M | |||
| Net Income (TTM) | -58.96M | |||
| Net Income Avl. to Common (TTM) | -58.96M | |||
| Total Revenue Growth (Q YOY) | -19.06% | |||
| Earnings Growth (Q YOY) | 3.21% | |||
| EPS Diluted (TTM) | -0.59 | |||
| EPS Diluted Growth (Q YOY) | 55.78% | |||
| Balance Sheet | GENN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 212.07M | |||
| Cash Per Share (Q) | $1.87 | |||
| Total Current Assets (Q) | 869.13M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -1.16B | |||
| Current Ratio (Q) | 0.226 | |||
| Book Value Per Share (Q) | -$7.35 | |||
| Total Assets (Q) | 4.06B | |||
| Total Current Liabilities (Q) | 3.84B | |||
| Total Debt (Q) | 3.81B | |||
| Total Liabilities (Q) | 5.22B | |||
| Total Common Equity (Q) | -820.22M | |||
| Cash Flow | GENN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -33.53M | |||
| Cash from Financing (TTM) | -94.79M | |||
| Net Change in Cash (TTM) | 187.41M | |||
| Levered Free Cash Flow (TTM) | -134.77M | |||
| Cash from Operations (TTM) | 315.73M | |||
